- Home
- GNFT vs TKNO Comparison
GNFT vs TKNO Comparison
Compare GNFT & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- TKNO
- Stock Information
- Founded
- GNFT 1999
- TKNO 1996
- Country
- GNFT France
- TKNO United States
- Employees
- GNFT N/A
- TKNO N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- GNFT Health Care
- TKNO Health Care
- Exchange
- GNFT Nasdaq
- TKNO Nasdaq
- Market Cap
- GNFT 249.0M
- TKNO 244.7M
- IPO Year
- GNFT 2019
- TKNO 2021
- Fundamental
- Price
- GNFT $6.06
- TKNO $5.45
- Analyst Decision
- GNFT Strong Buy
- TKNO Buy
- Analyst Count
- GNFT 1
- TKNO 2
- Target Price
- GNFT $13.00
- TKNO $5.00
- AVG Volume (30 Days)
- GNFT 26.3K
- TKNO 122.3K
- Earning Date
- GNFT 09-19-2024
- TKNO 11-07-2024
- Dividend Yield
- GNFT N/A
- TKNO N/A
- EPS Growth
- GNFT N/A
- TKNO N/A
- EPS
- GNFT 0.47
- TKNO N/A
- Revenue
- GNFT $86,225,222.00
- TKNO $34,940,000.00
- Revenue This Year
- GNFT $155.44
- TKNO $3.22
- Revenue Next Year
- GNFT N/A
- TKNO $14.88
- P/E Ratio
- GNFT $12.34
- TKNO N/A
- Revenue Growth
- GNFT 175.45
- TKNO N/A
- 52 Week Low
- GNFT $2.97
- TKNO $1.16
- 52 Week High
- GNFT $6.08
- TKNO $5.47
- Technical
- Relative Strength Index (RSI)
- GNFT 69.91
- TKNO 62.45
- Support Level
- GNFT $5.41
- TKNO $4.76
- Resistance Level
- GNFT $5.84
- TKNO $5.07
- Average True Range (ATR)
- GNFT 0.30
- TKNO 0.36
- MACD
- GNFT 0.04
- TKNO 0.02
- Stochastic Oscillator
- GNFT 98.03
- TKNO 98.27
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.